Medios AG

Medios achieves double-digit growth in 2023 – Positive outlook for 2024

Medios acquires Dutch market leader in pharmaceutical compounding services

Medios acquires Dutch market leader in pharmaceutical compounding services

Medios AG: Supervisory Board extends contracts with members of the Executive Board Mi-Young Miehler and Christoph Prußeit

Medios records strongest quarter in the Company’s history

Medios AG: Strong operating cash flow – record figures as expected also for revenue and earnings in the third quarter of 2023

Medios AG: achieves further growth in the first half of 2023 and expects strong third quarter

Medios AG: Christoph Prußeit, buy

Medios AG: Annual General Meeting re-elects Dr. Yann Samson, Joachim Messner and Klaus J. Buß to the Supervisory Board

Medios AG centralizes blister business at one site and sells Kölsche Blister GmbH

Medios AG: Supervisory Board extends contract with Chief Financial Officer Falk Neukirch

Medios AG: starts successfully into the 2023 financial year

Medios AG expects continued growth after record year in 2022 and plans further increase in profit margin

Medios AG: Record revenue and earnings – Guidance 2022 achieved; further growth expected in financial year 2023

Medios AG: Successful completion of the acquisition of bbw – Significant expansion of compounding volume

Medios AG presents growth strategy and announces medium-term targets at Capital Markets Day 2022

Medios AG: Acquisition of Blisterzentrum Baden-Württemberg GmbH and expansions in the area of sterile manufacturing

Medios AG continues growth course in the first nine months of 2022 – guidance for the 2022 financial year confirmed